About us
VEL Sciences is a pre-IND, pre-clinical, biotechnology company developing immunotherapeutics against Cancer and against antigenically variable pathogens (AVPs) and infectious diseases (such as: HCV, HIV, TB, Coronavirus, malaria, influenza, dengue/zika, etc.).
It is a closely held partnership between critical scientists, medical experts, and financial experts. VEL Sciences evolved with the intent of greatly improving the efficiency and productivity in the development of vaccines. In addition, the revolutionary and patented platform is a groundbreaking resource for the proactive development of prophylactic and immunotherapeutic drugs.
In addition to our own pipeline of drugs, we intend to offer our platform to other biotechs in order to improve their past, present, and future research and development assets.
We intend to disrupt the presently reactive nature of vaccine development by further developing the only proactive platform that can anticipate future mutations and embed those immunologics into the body to fight future iterations of a virus or cancer.
In addition, our goal is to save $100 Billion a year globally so that these funds can be used for more important domestic issues like food, clean water, and education.
.png)
Keith Jay Raphael
Co-Founder and Co-CEO
Keith brings 43 years of diverse institutional financial, banking, and fiduciary experience to Vel Sciences. Until October of 1993, he served as Vice-President and Global Chief Technical Market Analyst at Chase Manhattan Bank in New York City. Since 1993, Keith, as President of Crosscurrents Investments, provides risk management and alternative investments to their diverse Institutional, Governmental, and Ultra High Net Worth investors and Family Offices. Keith is also presently the Fiduciary Advisor Metabolics LLC, the producer of the revolutionary diabetes medical device. Keith is finalizing a Series “A” $100 million financing round for VEL Sciences.
.jpg)
Karen Manoutcharian
Chief Science Officer
Karen is the original designer of the VEL concept. He serves as a senior researcher at the Institute for Biomedical Research at Universidad Nacional Autónoma de México, and has been active in biomedical research for his entire career. He is a frequent contributor and author of academic papers in biomedical research and immunology (ref. publications attached). Karen brings to VEL Sciences more than 29 years of research There are presently a team of 4 researchers in his laboratory working on VEL research.
.png)
Eric Garafano
Co-Founder and Co-CEO
Eric brings to VEL Sciences executive experience developing technologies and strategies for the life sciences and technology markets. Most recently, serving as CFO of Primex Clinical Laboratories, Inc., a high-complexity clinical laboratory. Mr. Garofano has been responsible for creating new technologies and identifying their applications within the Life Sciences industries; he founded companies that designed and distributed biologics products and designed and manufactured implantable medical devices and treatment innovations for osteo/osteochondral applications. He has achieved numerous FDA approvals.
.png)
Oshin Harootoonian
Chief Operations Officer
Oshin Harootoonian brings to VEL Sciences 26 years of experience as a healthcare executive and founder of Primex Clinical Laboratories, Inc. A high-complexity clinical laboratory. Primex provides clinical diagnostic testing services to thousands of clients throughout California, Nevada, and American Samoa. He formed strategic partnerships with Thermo Fisher, Siemens, Beckman, and Bio-Rad and enabled Primex to become one of the first labs asked to join the Covid Testing Task Force for the State of California.